MARKET

EMMA

EMMA

Emmaus Life Scie
OTCMQB
0.013
NaN%
Closed 09:30 01/16 EST
OPEN
--
PREV CLOSE
0.013
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.040
52 WEEK LOW
0.0086
MARKET CAP
830.25K
P/E (TTM)
-0.1138
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EMMA last week (0112-0116)?
Weekly Report · 19h ago
Weekly Report: what happened at EMMA last week (0105-0109)?
Weekly Report · 01/12 09:40
Weekly Report: what happened at EMMA last week (1229-0102)?
Weekly Report · 01/05 09:38
Emmaus Life Sciences grants NeoImmuneTech Endari distribution rights
TipRanks · 12/31/2025 11:35
EMMAUS LIFE SCIENCES INC - ENTERS LICENSE AND DISTRIBUTION AGREEMENT WITH NEOIMMUNETECH
Reuters · 12/30/2025 21:30
EMMAUS LIFE SCIENCES INC - AGREEMENT INCLUDES UPFRONT PAYMENT AND ROYALTY ON NIT'S SALES
Reuters · 12/30/2025 21:30
Emmaus Life Sciences Grants NeoImmuneTech Exclusive North American Rights to Endari
Reuters · 12/30/2025 21:30
Emmaus Life Sciences Announces Strategic Transaction
Barchart · 12/30/2025 15:30
More
About EMMA
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing and sale of treatments and therapies, primarily for rare and orphan diseases. Its lead product, Endari (prescription grade L-glutamine oral powder) helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. The Company has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.

Webull offers Emmaus Life Sciences Inc stock information, including OTCMQB: EMMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EMMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EMMA stock methods without spending real money on the virtual paper trading platform.